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1. Introduction
Cell therapy encompasses a broad clinical 
territory in which transplanted cells are 
used to terminate or reverse an assortment 
of disease processes, such as cardiovas-
cular disease,[1,2] diabetes,[3] autoimmune 
disorders,[4] neurodegenerative disease,[5,6] 
and cancer.[7] The last decade has seen an 
exponential advancement of cell therapy 
technologies, with promising preclinical 
results finally yielding substantial clinical 
benefit using Chimeric Antigen Receptor 
T-cell (CAR T) for treatment of hemato-
logic malignancies.[8–10] However, despite 
these isolated clinical successes, other cell 
therapy approaches have provided only 
a modest clinical benefit, which may be 
attributed to poor cell retention and sur-
vival at the disease site.[11–13]
A delivery system that facilitates 
regional and repeated delivery to target 
Regenerative medicine approaches, specifically stem cell technologies, have 
demonstrated significant potential to treat a diverse array of pathologies. However, 
such approaches have resulted in a modest clinical benefit, which may be attributed 
to poor cell retention/survival at the disease site. A delivery system that facilitates 
regional and repeated delivery to target tissues can provide enhanced clinical 
efficacy of cell therapies when localized delivery of high doses of cells is required. In 
this study, a new regenerative reservoir platform (Regenervoir) is described for use 
in large animal models, with relevance to cardiac, abdominal, and soft tissue pathol-
ogies. Regenervoir incorporates multiple novel design features essential for clinical 
translation, with a focus on scalability, mechanism of delivery, fixation to target 
tissue, and filling/refilling with a therapeutic cargo, and is demonstrated in an array 
of clinical applications that are easily translated to human studies. Regenervoir con-
sists of a porous reservoir fabricated from a single material, a flexible thermoplastic 
polymer, capable of delivering cargo via fill lines to target tissues. A radiopaque 
shear thinning hydrogel can be delivered to the therapy reservoir and multiple fixa-
tion methods (laparoscopic tacks and cyanoacrylate bioadhesive) can be used to 
secure Regenervoir to target tissues through a minimally invasive approach.
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tissues can provide enhanced clinical efficacy of cell therapies 
when localized delivery of a high dose of cells is required. For 
example, direct delivery of cells to the intraperitoneal space 
can improve clinical benefit compared to systemic intravenous 
administration. Stem cells delivered to the intraperitoneal space 
show a substantial preclinical benefit in treatment of inflam-
matory bowel disease[14,15] and rheumatoid arthritis[16,17] com-
pared to intravenous therapy. Intraperitoneal infusion with 
CAR T-cells can also reduce tumor burden in animal models 
of peritoneal carcinomatosis,[18] with repeat dosing leading 
to an improved response.[19,20] Intramuscular delivery of cells 
to skeletal muscle has also been used for treatment of critical 
limb ischemia[21–24] and skeletal muscle regeneration,[25–27] obvi-
ating the need for localized delivery of cells to intramuscular 
targets. Cardiac tissue may also benefit from direct cell delivery 
compared to systemic administration; for example, implanta-
tion of stem cells in the heart leads to improved retention[28] 
and cardiac function after myocardial infarction via paracrine 
mediators,[11–13] and several studies in rodents suggest repeated 
dosing provides functional improvement compared to a single 
infusion of cells.[29–33]
In order to address the need for local, repeated delivery of 
cells after myocardial infarction, we previously developed a 
refillable, flexible polymer reservoir that enabled delivery of 
multiple doses of mesenchymal stem cells (MSCs) to ischemic 
cardiac tissue in a small animal model of acute myocardial 
infarction. Repeated dosing of MSCs resulted in improved 
ejection fraction and fractional shortening, and established 
the therapeutic value of an implantable reservoir that permits 
repeated dosing of cellular cargo.[33] No such device exists for 
large animal models.
In this report, we expand upon this earlier work with a feasi-
bility study where a new regenerative reservoir platform (Regen-
ervoir) is designed and manufactured for use in three large 
animal models that are easily translated to human studies, a 
significant leap forward. The Regenervoir system was designed 
for use in a diverse set of clinical applications, and incorporates 
multiple novel design features essential for clinical translation, 
with a focus on scalability, mechanism of delivery, fixation to 
target tissue, and filling/refilling with a therapeutic cargo. We 
generated a porous reservoir out of a single material, a flex-
ible thermoplastic polymer, capable of delivering cargo via fill 
lines to target tissues. We used a radiopaque shear thinning 
hydrogel for reservoir filling, and tested minimally invasive fix-
ation methods comparing laparoscopic tacks with cyanoacrylate 
bioadhesive. We then validated the Regenervoir design fea-
tures and deployment systems in three different large animal 
models with relevance to cardiac, abdominal, and soft tissue 
pathologies.
The Regenervoir system provides regional delivery of ther-
apeutic cellular cargo to multiple different target tissues. The 
overall design concept, independent of clinical application, 
incorporates a refill line which connects to one or multiple 
loading chambers that house the therapeutic cargo. Each 
loading chamber has an active surface, consisting of a semiper-
meable membrane that allows for the therapeutic cargo housed 
within the chamber to interact with the host environment via 
direct contact or paracrine mechanisms. The overall Regener-
voir concept is then tailored to specific clinical scenarios with 
intended targeting to three distinct tissue types: intraperitoneal 
(ip-Regenervoir), intramuscular (im-Regenervoir), and cardiac 
(c-Regenervoir). All three designs allow a platform than can 
target the needs of loco-regional delivery in a minimally inva-
sive manner using indication specific cargoes. Each version 
of Regenervoir was developed for deployment with a unique 
delivery system as deployment of each configuration has 
design challenges as they are constrained in different dimen-
sions based on the anatomical location. For each design, ease of 
deployment, tissue/organ contacting, alignment to current clin-
ical treatment paradigm, and correct orientation of the reservoir 
were the common rationale design elements. The ip-Regener-
voir system is delivered to the intraperitoneal space through a 
minimally invasive procedure utilizing a percutaneous delivery 
sheath for targeting of intra-abdominal pathology. In this con-
figuration, we show the importance of understanding deploy-
ment and orientation with anatomical relations and also the 
fixation requirements in a wet space using a currently approved 
fixative. The im-Regenervoir system is positioned between 
muscle layers, with securement to the fascia via a minimally 
invasive scope and trocar system, providing a means for tar-
geting various soft tissues through an endoscopic procedure. 
In this configuration, we show that space can be created and a 
reservoir deployed in an atraumatic manner and secured with 
current fixation tools. Finally, the c-Regenervoir system is deliv-
ered through a minimally invasive incision in the chest (mini-
thoracotomy) and wrapped around the left ventricle, providing 
targeted delivery directly to the epicardium of the heart. This 
configuration demonstrates anchoring to a dynamic organ, 
deployment on a curved surface that requires unsheathing 
and orientation in a limited space (pericardium) while working 
through a visually limiting mini-thoracotomy.
2. Results and Discussion
2.1. Regenervoir Fabrication
We utilized a soft, flexible thermoplastic polymer (thermo-
plastic polyurethane, or TPU) for the production of the entire 
reservoir frame (Figure  1a). The use of TPU allowed us to 
incorporate a variety of manufacturing elements into the 
Regenervoir housing, such that a single material was manipu-
lated to provide a broad range of design features. The loading 
chambers were generated using a vacuum thermal former and 
a custom 3D printed mold. Size, positioning, and orientation 
were modified depending on the clinical application. An outer 
channel was added around the loading chamber by heat sealing 
two layers of TPU around water soluble paper which was sub-
sequently washed out. This enabled fabrication of a separate 
channel from the loading chamber, for remote delivery of an 
adhesive for fixation. Internal struts were added to the loading 
channel with an additional heat sealing phase, in which TPU 
layers were focally bonded over a 3D printed mold in a heat 
transfer machine. Fill or purge lines were secured to the Regen-
ervoir system by heat bonding TPU catheter tubing directly to 
excess material surrounding the loading chamber.
The active surface of Regenervoir consists of a porous layer 
of TPU that facilitates the therapeutic effect of cellular cargo. 
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A laser cutting technique was used to generate pores from 
10 to 100 µm in diameter. Pore size, pattern, and density can be 
varied depending on the specific clinical need, with larger pores 
allowing migration of the cellular cargo outside of the loading 
chamber, while pores <10  µm provide an immune-protective 
barrier (via size exclusion of immune cells) but still allow dif-
fusion of macromolecules and paracrine factors (Figure  1b). 
We do not claim complete immune isolation with this pore 
size, but the design is modular to allow the incorporation of 
membranes with smaller pore size as previously described,[33] 
if necessary.
The use of TPU as the chamber support material also allowed 
us to incorporate novel design features into the device that 
permit delivery, filling, and fixation of the Regenervoir system. 
With the addition of TPU tubing, we are able to generate the 
entire implant from a single material, one with a favorable bio-
compatibility profile when loaded with cells and implanted in 
rodents.[33,34] The flexible nature of the completed devices also 
enables them to be used in low profile delivery systems, such that 
a minimally invasive procedure can be utilized for implantation.
The fill line enables repeated loading of therapeutic cells 
within the chamber. To preserve the viability of cells during 
Adv. Healthcare Mater. 2020, 9, 2000305
Figure 1. Fabrication of porous reservoirs a) Fabrication of Regenervoir; thermoforming with 3D printed molds enables precise reservoir dimensions 
with different fill patterns. Heat sealing over 3D printed molds enables 2D patterning of flat reservoirs. Heat Sealing with water soluble paper allows 
layered overlapping compartments for different channels (adhesive and therapy channels). b) Laser cutting provides controlled porosity at multiple 
sizes and densities (Left to right: High density 100 µm pores, low density 100 µm pores, 10 µm pores).
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infusion and after delivery to the loading chamber, we devel-
oped a biomaterial carrier to provide a support matrix that not 
only enhances cell viability, but also has favorable rheological 
properties that enable infusion through small bore tubing. 
Iodixanol HA hydrogel, a hyaluronic acid (HA)-based shear-
thinning hydrogel incorporating a commercially available Iodix-
anol contrast agent, was used in this study as a therapeutic 
cargo analog that allows visualization during deployment. The 
shear thinning nature of the hydrogel facilitates delivery to 
the device. While the presence of the Iodixanol in the HA gel 
results in an increase in resting viscosity it has a comparable 
rheological profile in terms of shear thinning to HA hydrogel 
alone as shown in Figure 2a, making it a valuable demonstrator 
material. We have previously reported cell viability in a cross-
linkable version of this HA hydrogel.[35,36] MicroCT imaging 
of a device with reservoirs filled with different concentrations 
of Iodixanol HA hydrogel was performed which enabled us to 
generate a 3D model of the filled device highlighting the dif-
ferent compartments (Figure 2b).
In order to secure the Regenervoir system to underlying 
tissue, we tested two different fixation methods compatible with 
existing clinical procedures. First, a medical grade cyanoacrylate 
Adv. Healthcare Mater. 2020, 9, 2000305
Figure 2. Filling and adhesion of the porous reservoirs. a) Viscosity in response to increase shear stress of HA 1%w/v hydrogel and Iodixanol 11.85%w/w/
HA 1.1%w/v hydrogel. Iodixanol hydrogel and HA 1%w/v show comparable shear thinning (reduction in viscosity) on application of stress. Data shown 
representative of the norm (n = 3). Inset radiopaque hydrogel is a clear colorless liquid. b) microCT of filled device with reservoir (blue) and adhesive 
channel (yellow). c) Force versus strain (%) curve showing adhesive behavior of bioadhesive. d) Force versus strain (%) curve showing adhesive 
behavior of tissue tasks. e) Maximum pull-off forces for bioadhesive compared to tissue tacks (n = 5−6/group, p = 0.25). f) % viability of hMSCs after 
delivery through 100 µm pores and to each configuration of Regenervoir compared to delivery through a standard syringe with an 18 g needle (control).
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bioadhesive was administered through a separate fill line with 
attachment points around the periphery of the device. This is 
illustrated in the 3D imaging shown in Figure  2b, with res-
ervoir for therapeutic cargo shown in blue and the adhesive 
channel shown in yellow. For endoscopic fixation, the device 
was secured with a commercially available laparoscopic tacking 
device. We then compared adhesion force of the bioadhe-
sive and the tissue tacks adhered to freshly harvested porcine 
muscle tissue, which was recorded using a lap shear pull-off 
test set-up. No significant difference was observed between the 
tissue fixation modalities, tissue tack compared to bioadhesive 
(4.31  ±  2.22  vs 5.82  ±  2.38 N, p  =  0.25), indicating both tech-
niques are suitable for in vivo use. The mode of failure was 
noted to be slightly different between the two methods, likely 
due to the fact that the bioadhesive acts on a larger surface area 
of muscle tissue (Figure 2c–e).
To demonstrate feasibility of cell delivery, we delivered 
33  ×  104 human mesenchymal stem cells (hMSCs)   mL−1 to 
each configuration of Regenervoir and through devices with 
100  µm pores and determined the percentage viability com-
pared to delivery through a standard syringe with an 18 g 
needle (control). We found >90% viability with no significant 
differences between the groups (Figure 2f) showing feasibility 
of cell delivery to the Regenervoir devices and also through the 
100 µm pores.
2.2. Validation of Regenervoir Concept in Large Animal Models
2.2.1. ip-Regenervoir
We first sought to establish the intraperitoneal space as a tissue 
target using a procedure translatable to humans with the ip-
Regenervoir system. The ip-Regenervoir device consists of an 
inner loading chamber that can be infused with therapeutic 
cells, and an outer bio adhesive channel (Figure 3a) which can 
be filled with a bio adhesive to secure the loading chamber to 
surrounding tissues. Prior to proceeding with in vivo testing, 
we confirmed device functionality with benchtop testing. Filling 
the loading chamber and bioadhesive channel with aqueous 
dye solutions highlights the separate filling of the different 
channels (Figure 3a; and Movie S1, Supporting Information).
The ip-Regenervoir and delivery system were designed to be 
compatible with the skillset of clinicians who perform image-
guided procedures (e.g., interventional radiologists), ensuring 
that the technology is easily adapted for clinical use. A percu-
taneous approach is an established method for accessing the ip 
space for tissue biopsies and drain placement.[37] Therefore, we 
devised a percutaneous, over-the-wire approach to position the 
ip-Regenervoir in the abdominal cavity (Figure 3b) based on the 
Seldinger technique.[38] The greater omentum is a highly vascu-
larized bed of adipose and connective tissue that supports the 
blood supply to the mesentery. It serves as an ideal anatomic 
target for device delivery, as it offers direct access to the ip space 
and has been used to support pancreatic islet implants for treat-
ment of diabetes.[39,40] The greater omentum also presents a 
low risk intra-abdominal implant site, as complications such 
as intestinal perforation or bowel obstruction are rare, and a 
free flap of omentum is often mobilized for wound coverage 
or protection of implanted prosthetic.[38] In swine the greater 
omentum consists of a highly vascular thin layer of tissue that 
is adherent to the anterior wall of the stomach, which serves 
as a useful landmark to guide device positioning. Wire access 
to the ip space was obtained using ultrasound guided place-
ment of a 16  g needle. The wire was then positioned in the 
appropriate intra-abdominal compartment using a combina-
tion of fluoroscopic and ultrasound guidance (Figure 3c,d). The 
device was then loaded into a 30 Fr sheath and deployed over 
the omentum and oriented with the active surface directed to 
the posterior surface of the animal. The orientation of the active 
surface was confirmed with a radiopaque c-shaped marker at 
the distal end of the device (Figure 3e) and wires and sheaths 
were removed. A syringe was then used to inject solution into 
the bioadhesive channel. Cyanoacrylate has been used exten-
sively in surgical procedures for tissue adhesion[41] and embo-
lization[42] and specifically has been used to secure synthetic 
meshes to the abdominal wall during hernia repair.[43] We there-
fore utilized a medical grade cyanoacrylate for fixation, and the 
device was allowed to bond to surrounding tissue for 5 min. 
Once we confirmed that the device was positioned appropri-
ately, the animal was euthanized, and a CT scan was performed 
of the animal. The ip-Regenervoir was identified in a 3D ren-
dering of the intact specimen, and cross-sectional imaging 
confirmed appropriate placement of the device (Figure  3f,g). 
Postmortem dissection confirmed that the device was in the 
appropriate place, and the cyanoacrylate was adherent to the 
omental tissue (Figure 3h).
2.2.2. im-Regenervoir
The im-Regenervoir system was designed for cellular delivery 
to intramuscular targets, using a minimally invasive delivery 
system congruent with current surgical techniques. Endoscopic 
techniques are widely used for the repair of abdominal wall 
defects, such as inguinal hernias[44,45] and ventral hernias.[46] 
During these procedures, a potential space between muscle 
layers is accessed and expanded to accommodate a prosthetic 
implant (typically a hernia mesh) or to facilitate primary repair 
of the abdominal wall defect. The fascial plane between the 
internal and external oblique muscles of the anterior abdominal 
wall is a representative intramuscular implant site as it is easily 
accessible in the pig, and similar in size to that of humans. 
Therefore, we demonstrated the clinical validity of the im-
Regenervoir, through delivery and deployment of the device to 
the abdominal wall of a pig, and in doing so exploited existing 
surgical techniques for abdominal wall reconstruction. The 
loading chamber consists of a continuous square wave pattern 
with fill and purge lines (Figure 4a; and Movie S2, Supporting 
Information). The loading chamber pattern was selected to max-
imize surface area of the active surface of the device. An endo-
scopic technique was used for device delivery (Figure  4b). The 
fascial plane between the muscles was first separated using a 
space creating balloon, then expanded with CO2 insufflation. A 
single visualization port and two working ports were placed in 
the potential space, and the im-Regenervoir was rolled so that 
it could be compressed into a 10  mm laparoscopic trocar. The 
im-Regenervoir was then delivered into the insufflated space, 
Adv. Healthcare Mater. 2020, 9, 2000305
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opened and positioned under direct visualization. The edges of 
the device were secured to the underlying internal oblique fascia 
using a laparoscopic tacking device (Figure 4c), and radiopaque 
contrast was injected into the fill line under fluoroscopic guid-
ance to verify channel patency (Figure  4d). Postmortem exam 
confirmed proper placement of the device after the procedure.
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Figure 3. Percutaneous delivery of ip-Regenervoir to the omentum. a) Rendering and produced unit of reservoir system with adhesive (yellow) and thera-
peutic (blue) channels filling. b) Schematic of procedure for percutaneous delivery to the intraperitoneal space. c) Micrograph of ultrasound guided needle 
access. d) Ultrasound guided access of the left upper quandrant is used for positioning of device on omentum. A guidewire is used to position a delivery 
sheath in the tissue plane of the omental fat. e) Fluoroscopy enables visualization of the adhesive channel (filled with contrast here) after implantation, 
with a distal radiopaque marker to guide orientation of the reservoir. f) 3D rendering of a computed tomography scan of a pig after percutaneous delivery 
of the reservoir system confirms intra-abdominal positioning. g) A deployed device (blue) is seen on both axial (i) and coronal (ii) slices. h) After infusion 
of the adhesive channel with cyanoacrylate, the device can be seen fixed to the greater omentum, which overlies the stomach (*** = greater omentum).
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2.3.1. c-Regenervoir
Congestive heart failure, characterized by poorly functioning 
myocardium as a result of prior myocardial ischemia or con-
genital abnormalities, is a growing burden on healthcare 
systems worldwide.[47,48] As treatment paradigms evolve to 
include cell and biomaterial-based therapies to improve heart 
function, novel delivery strategies are necessary to deliver 
these treatments.[2] Although alternative strategies have been 
devised for delivery of biomaterials and cells to the heart 
in minimally invasive fashion, including a biodegradable 
polymer reservoir,[35] a hydrogel patch,[49] and a flexible injec-
tion catheter,[50] a refillable depot that can be secured to the 
heart has not yet been established. The c-Regenervoir system 
aims to address this unmet need, by creating a multidepot 
reservoir that wraps around the left ventricle to secure focal 
delivery of therapeutic cargo. The c-Regenervoir consists of 
nine loading chambers linked in series with a fill line to allow 
loading of the device (Figure 5a). Infusion with an aqueous 
dye shows equitable filling of all loading chambers. The 
exact number and positioning of loading chambers can be 
modified according to the specific patient needs. If a patient 
is suffering primarily from an infarct of the intraventricular 
septum, the layout of chambers can be modified so that the 
impact of cargo is centered on the intraventricular septum. A 
separate channel for bioadhesive was also included to permit 
fixation to tissue (Figure  5a; and Movie S2, Supporting 
Information).
The cardiac configuration of Regenervoir was designed to 
be deployed through a sheath placed through a small inter-
costal incision (mini-thoracotomy), Figure 5b. To enable precise 
delivery of the multichambered reservoir, we designed a mini-
mally invasive delivery system to wrap c-Regenervoir around 
the heart. A shape-memory nitinol frame was developed that 
molds the Regenervoir system to the silhouette of the under-
lying ventricle (Figure  5c). A soft vacuum gripper tempo-
rarily adheres to the apex of the heart to enable stabilization 
of the dynamic organ during device delivery and placement. 
The c-Regenervoir is advanced out of a delivery sheath with the 
shape-memory nitinol frame expanding to its ventricular confir-
mation, enabling precise guidance and placement of the reser-
voir around the heart (Figure 5d). Once the reservoir is adhered 
Adv. Healthcare Mater. 2020, 9, 2000305
Figure 4. Laparoscopic delivery of im-Regenervoir to the omentum. a) Rendering and physical prototype of im-Regenervoir system with adhesive 
(yellow) and therapeutic (blue) channels. b) Schematic of the procedure for laparoscopic delivery to the intramuscular space. c) Fixation of the im-
Regenervoir using a laparoscopic tacking device with tack position confirmed (i). d) Filling of the therapy channel under fluoroscopy.
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to the epicardial surface, the nitinol frame is withdrawn back 
into the sheath, leaving the c-Regenervoir fixed in place.
We then tested delivery of the c-Regenervoir system under 
direct and fluoroscopic visualization by applying it to the epi-
cardial surface via a median sternotomy in a swine model. We 
show filling of the reservoirs through the fill line with con-
trast agent (Figure  5e(i)) and dye (Figure  5e(ii)). Finally, we 
show that the fill lines can be used as a conduit for tracking 
microcatheters to specific reservoirs for more targeted delivery 
(Figure  5e(ii)) and we envisage this as a potential biopsy 
approach if required.
3. Conclusion
As the multitude of disease targets that can be treated with cell 
therapy continues to expand, new technologies are needed to 
augment the therapeutic potential of these cells through regional 
and repeated delivery to select tissues. Here we describe a flexible 
monomaterial polymeric reservoir that can be used to enhance 
the efficacy of cell therapies in diverse clinical scenarios. We can 
scale this reservoir to large animal models, while still allowing 
low profile, minimally invasive delivery, aligned to common 
interventional procedures. We show predictable deployment of 
Adv. Healthcare Mater. 2020, 9, 2000305
Figure 5. Epicardial delivery of a Regenervoir to the heart. a) Rendering of reservoir system with multiple depots for wrapping around the left ventricle. 
b) Schematic of the mini-thoracotomy procedure. c) Schematic of positioning and deployment of the reservoir on a moving heart including suction 
and polytetraflueoroethylene (PTFE) guidance arms. d) Steps for positing and deploying the cardiac reservoir. e) Filling of the cardiac reservoir on 
the heart during an open chest procedure including fluoroscopy and photographic images of global reservoir filling (i,ii) and a fluoroscopic image of 
targeted reservoir filling by a microcatheter (iii).
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the reservoirs at the target site using channels embedded in the 
reservoirs, a strategy that is easily translated to human studies. 
Choosing a single thermoplastic materiel to fabricate the reser-
voir structure allowed us to incorporate novel design features to 
achieve fixation and filling of the Regenervoir system in three 
distinct settings. Further, the ability to laser cut the material ena-
bles facile porosity tuning to facilitate the unique cell delivery 
requirements associated with a multitude of disease targets 
(e.g., cell migration, cell isolation, and cell immune-isolation). 
For clinical translation, we envisage the Regenervoir enabling 
multiple discrete therapy refills through injection into a subcu-
taneous port, or alternatively, connecting the therapy line to a 
controlled delivery infusion pump, such as those currently used 
in the clinic for insulin delivery, for continuous therapy infu-
sion. In summary, we feel that this versatile platform presents 
a significant enhancement over current reservoir platforms for 
cell/drug delivery due to the multifunctionality (minimally inva-
sive delivery, in situ deployment, adhesion, and tunable therapy 
delivery) enabled by a functionalized monomaterial reservoir.
4. Experimental Section
Fabrication of Reservoir System: The manufacturing technique for 
the Regenervoir systems is shown in Figure  1. 0.3  mm thick TPU 
sheets for the loading chamber and 0.075  mm TPU sheets for the 
membrane and channels (HTM-8001-M and HTM-1001 polyether TPU 
film, American Polyfilm, Inc) were utilized. The loading chambers 
were formed into desired shapes based on a 3D printed mold for each 
prototype (intraperitoneal, intramuscular, or cardiac). 3D molds were 
designed with Autodesk Inventor and printed with a Formlabs2 printer. 
The loading chamber was shaped using a vacuum thermal former 
(450DT, Formech). To incorporate a bioadhesive channel, a section of 
water soluble paper (2301S Print-Stitch-Dissolve, Pellon) was secured 
between two 0.075 mm TPU sheets which were then heat bonded using 
a heat transfer machine (Heat Transfer Machine QXAi, Powerpress). 
Perforations to allow for diffusion of bioadhesive were made using a 21 
gauge needle. The fill lines were added using thermoplastic polyurethane 
catheter tubing (ID = 1 mm, OD = 1.97 mm, MRE 080 Micro-Renathane, 
Braintree scientific) which was bonded to this assembly using a heat 
transfer machine. This reservoir interfaces with soft tissue via the TPU 
membrane which can have pores of variable size. 10–100  µm pores 
(National Centre for Laser Applications, National University of Ireland 
Galway) were generated in the TPU membrane.
Fabrication of c-Regenervoir Delivery System: To create the nitinol frame, 
0.5  mm superelastic Nitinol wire (Nexmetal Corp) was fixed around a 
ventricular shaped stainless-steel mold and annealed in a furnace at 500 °C 
for 30 min. The shape-set nitinol frame was then secured around the end 
of a catheter (4.5 mm ID, 6 mm OD). The soft, silicone suction cup gripper 
(Ecoflex 00-20) was attached to the end of a vacuum line (3 mm ID, 4 mm 
OD) and placed within the inner lumen of the catheter. The c-Regenervoir 
was fabricated as described previously, with the addition of four TPU 
sleeves on the back of the reservoir. PTFE sheaths (2 mm ID, 3 mm OD, 
Allen Tech) were inserted into each of the four sleeves to serve as guides 
for the nitinol arms and to reduce friction between the device and the 
nitinol arms during device deployment. The c-Regenervoir was loaded onto 
the nitinol frame, with the four nitinol arms sliding into the PTFE sheaths. 
The entire system was then loaded within a delivery sheath (9  mm ID, 
13  mm OD) and was ready for use. After guiding the delivery sheath 
through the intercostal space and into the thoracic cavity, the surgeon can 
move the suction cup gripper and the nitinol frame independently within 
the sheath for optimal device placement and deployment.
Production of Shear Thinning Hydrogel: A HA-based hydrogel 
incorporating a contrast agent was used in this study. The hydrogel, 
herein referred to as Iodixanol HA hydrogel, was required to have a shear 
thinning profile which facilitates injectability. The HA base hydrogel was 
prepared using a long chain, high molecular weight (≈1.1–1.3 MDa) HA 
polymer with no side chain substitution at a concentration of either 
1% or 1.447% w/v (for Iodixanol hydrogel) in purified water. Iodixanol 
(Visipaque 320  mg Iodine  mL−1, GE Healthcare) is a commercially 
available iodinated contrast agent. Incorporation into a hydrogel at a 
concentration of 9.22% w/w to create a radio opaque formulation is 
previously documented.[51] For these studies, the Iodixanol HA hydrogel 
was prepared in aliquots (11  mL) using a combination of 1.447% w/v 
HA hydrogel (9  mL) and Iodixanol (2  mL). These were mixed until 
homogeneous giving an Iodixanol HA gel at a final concentration of 
1.2% w/v HA and 11.85% w/w Iodixanol. Rheological properties were 
assessed using a Discovery Hybrid Rheometer HR-2 (TA instruments, 
USA). Viscosity of each hydrogel was measured by flow rheometry using 
cone and plate (40 mm cone geometry with 4° angle). All analysis was 
performed at a constant 25  °C with controlled shear stress applied 
across the range 1–30 Pa. All hydrogels were measured in triplicate and 
rheograms shown (Figure 2f) are representative of the norm.
Mechanical Testing of Tissue Fixation Modalities: A Zwick mechanical 
testing machine (Z050, Zwick/Roell) with a 100N load cell was used for 
pull-off testing to determine the adhesion forces of the tissue fixation 
modalities. Freshly harvested porcine abdominal muscle was cut into 
3 × 2 × 0.5 cm samples. 3 × 2 cm samples of TPU were prepared and 
1.5 cm of TPU was placed on top of the tissue. A single Poly-d, l-Lactic 
Acid (PDLLA) resorbable laparoscopic tack (Bard) was inserted into 
the center of the sample using the accompanying tack applier. The 
tissue cyanoacrylate (Histoacryl, B. Braun) was prepared following 
manufacturers protocol and tissue cyanoacrylate (100 µL) was injected 
onto the tissue before the TPU samples were placed on top, where 
1.5 cm of the TPU was glued to the tissue. The samples were mounted 
in the tensile tester using pneumatic clamps at 6 PSI, tests were ran 
at a shear rate of 20  mm  min−1 [52] and maximum lap shear force was 
recorded (n = 5–6 per group).
In Vitro Cell Viability: hMSCs were isolated from bone marrow 
aspirates obtained from human volunteers, at REMEDI, the National 
University of Ireland Galway. All procedures were carried out with 
informed consent and ethically approved by the Clinical Research Ethical 
Committee at University College Hospital, Galway. hMSCs were isolated 
using standard protocols and stringent analysis of cell phenotype 
as previously described.[53] hMSCs were cultured using low glucose 
Dulbecco’s modified Eagle’s medium (D6046, Sigma) supplemented with 
10% fetal bovine serum, 100 U mL−1 penicillin, 100 µg mL−1 streptomycin 
(Sigma-Aldrich, Ireland), and 5 ng mL−1 bFGF (R&D Systems) at 37 °C 
in a 5% carbon dioxide (CO2) environment. Cells were passaged at 
80–90% confluency, and were not used beyond passage 5. hMSCs 
were trypsinized, counted, and suspended in the media at a density of 
33  ×  104 cells  mL−1 before loading into a 10  mL standard syringe with 
an 18 g needle. Solution was slowly injected into each configuration of 
Regenervoir, through devices with 100  µm pores and compared to cell 
injection through the syringe and 18 g needle alone. The hMSC cell 
suspension was then diluted with Trypan blue. The assay was based on 
the permeable nature of the cell membrane in nonviable cells, whereby 
nonviable cells were stained blue on the addition of Trypan Blue solution, 
whereas viable cells excluded the dye and remain unstained. The cell 
concentration and viability were calculated by 2 blinded counters.
Animal Studies: Large animal testing of the ip-Regenervoir and 
im-Regenervoir devices were approved by the Italian Ministry of Health 
(No. 976/2017-PR) and performed at Explora Biotech Srl (Italy). Prior 
to the experiments, the animals were housed in single cages and were 
subjected to a 1 week acclimatization period following Directive 2010/63/
EU. Prior to surgery, animals received 10  mg  kg−1 ketamine (KetaVet 
100, MSD, Rome, Italy), 0.5  mg  kg−1 diazepam (Hospira, Naples, 
Italy). Anesthesia was induced by 5 mg kg−1 ketamine and 0.5 mg kg−1 
diazepam. After intubation, 2–3% isoflurane (IsoFlo, Esteve, Rome, 
Italy) was administrated by mask to maintain anesthesia. Following 
completion of the acute surgeries, animals were euthanized (IV injection 
of Tanax, 0.3 mL kg−1; MSD Animal Health Srl-Italy), and a postmortem 
© 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim2000305 (10 of 11)
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dissection was carried out to confirm positioning of the device. The total 
procedure lasted 6 h, where procedure implant time was ≈2 h, with in 
situ testing and imaging performed in the acute setting.
Intra-Abdominal and Intramuscular Delivery of Regenervoir: Female 
Landrace pigs, weighting 25–30  kg were utilized for these arms of the 
study. The ip-Regenervoir was delivered through the intraperitoneal space 
using an over-the-wire technique (n  =  4). The peritoneum was entered 
with an 18 g needle under direct ultrasound guidance using a 5–13 MHz 
linear probe (Esaote). A 0.035 in. guidewire was advanced over the greater 
omentum, and position was confirmed using fluoroscopy (to determine 
location of gastric bubble) and ultrasound. The delivery tract was dilated 
using an Amplatz renal dilator set (Boston Scientific), and a custom-
made 30 Fr sheath was advanced over the omentum. The ip-Regenervoir 
device was then delivered through the sheath, and positioning was 
confirmed with fluoroscopy (OEC 9800 Plus, GE HealthCare, Salt Lake 
City, UT), such that the active surface was directed toward the omentum. 
A cyanoacrylate adhesive (Histoacryle) was injected into the bioadhesive 
channel to bond the device to underlying tissue, and the device was filled 
with the HA/Iocixanol hydrogel. Following completion of the procedure, 
animals were euthanized (IV injection of Tanax, 0.3 mL kg−1; MSD Animal 
Health Srl-Italy). A postmortem CT scan (Siemens Syngo CT VC40-16-
slice) was obtained to confirm positioning of the device, and autopsy 
was carried out to verify deployment.
The im-Regenervoir system was delivered between muscles the 
abdominal wall (n = 2). A commercially available dissecting balloon and 
trocar (Spacemaker, Medtronic) was used to gain endoscopic access 
to the tissue plane posterior to the external oblique muscle, which 
was insufflated with continuous CO2 in order to maintain the space. 
Two 5  mm working ports were placed under direct visualization, and 
the device was rolled and passed through one of the ports sites to be 
introduced in the space. The im-Regenervoir device was positioned 
under direct endoscopic visualization, and secured at the corners using 
PDLLA laparoscopic tacks (Bard). The device was then filled with the 
HA/Iocixanol hydrogel under fluoroscopic visualization. Following 
completion of the procedure, animals were euthanized as above and an 
autopsy was performed to verify deployment.
Cardiac Delivery of c-Regenervoir: Preliminary feasibility of c-Regenervoir 
was tested on a porcine model. The acute porcine study was performed 
at the Boston Children’s Hospital, and the experimental protocol was 
approved by the hospital’s Institutional Animal Care and Use Committee. 
1 female Yorkshire swine (Parsons Farms) with a body weight of 60 kg was 
used. Anesthesia, lidocaine delivery, and monitoring were conducted as 
previously described.[54] Briefly, anesthesia was induced with a mixture 
of tiletamine/zolazepam HCl (Telazol, 4.5  mg  kg−1, Zoetis), xylazine 
(2 mg kg−1, Akorn), and atropine (0.04 mg Kg−1 intramuscularly, Westward). 
Isoflurane (0.5–1%, Baxter) in oxygen was used to maintain anesthesia. The 
animal was intubated after induction and mechanically ventilated using 
volume control at 10 mL kg−1 at a rate of 10–20 breaths min−1. Lidocaine 
was administered prophylactically to reduce the risk of ventricular 
arrhythmias caused by the epicardial positioning of c-Regenervoir. A bolus 
intravenous injection dose of lidocaine ranging from 0.5 to 1.5  mg  kg−1 
was administered at a rate of ≈0.35–0.7 mg kg−1 min−1. Continuous ECG 
tracings, arterial blood pressure, and central venous blood pressure 
were monitored through femoral lines, peripheral capillary, and oxygen 
saturation percentage. A median sternotomy was used to access the 
heart. The pericardium was removed and the c-Regenervoir was placed 
around the heart. The reservoirs were filled with contrast (Omnipaque, 
global filling or local filling with a microcatheter), while c-arm fluoroscopy 
(Siemens’ AXIOM Artis) was used for imaging and video capture. Dye 
was delivered to the reservoirs to visualize filling on a beating heart. 
Euthanization was conducted by an intravenous injection of sodium 
pentobarbitol (FatalPlus, 110 mg kg−1, Baxter).
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